Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

被引:2
|
作者
Ding, Shuo [1 ]
Guo, Wei [1 ]
Yin, Gaofei [1 ]
Li, Nuan [1 ]
Liu, Hongfei [1 ]
Huang, Junwei [1 ]
Yang, Zheng [1 ]
Xu, Hongbo [1 ]
Chen, Xiaohong [1 ]
Zhang, Yang [1 ]
Huang, Zhigang [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Squamous cell carcinoma of head and neck; clinical pathology; clinical protocols; SURVIVAL; CANCER;
D O I
10.21037/atm-22-2630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients. Methods: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I-IV, T1-4a, N0-2, M0). The intervention treatment methods for stage I-II patients are as follows: surgery, induction chemotherapy (IC) + surgery; surgery + adjuvant therapy; The intervention treatment methods for stage III-IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. Results: From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%. Conclusions: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The clinical value of serum squamous cell carcinoma 1 and 2 in head and neck squamous cell carcinoma
    Yasumatsu, Ryuji
    Nakano, Takafumi
    Hashimoto, Kazuki
    Kogo, Ryunosuke
    Wakasaki, Takahiro
    Nakagawa, Takashi
    [J]. AURIS NASUS LARYNX, 2019, 46 (01) : 135 - 140
  • [42] Phase 2 Study of Dasatinib in the Treatment of Head and Neck Squamous Cell Carcinoma
    Brooks, Heather D.
    Glisson, Bonnie S.
    Bekele, B. Nebiyou
    Ginsberg, Lawrence E.
    El-Naggar, Adel
    Culotta, Kirk S.
    Takebe, Naoko
    Wright, John
    Tran, Hai T.
    Papadimitrakopoulou, Vassiliki A.
    [J]. CANCER, 2011, 117 (10) : 2112 - 2119
  • [43] Pitfalls in the cytodiagnosis of metastatic squamous cell carcinoma in the head and neck: A retrospective study
    Karabi, Konar
    Sulekha, Ghosh
    Tapan, Ghosh
    Subodh, Bhattacharya
    Saurabh, Sanyal
    [J]. JOURNAL OF CYTOLOGY, 2008, 25 (04) : 119 - 122
  • [44] Phase II study of sunitinib malate in head and neck squamous cell carcinoma
    Choong, Nicholas W.
    Kozloff, Mark
    Taber, David
    Hu, H. Shawn
    Wade, James, III
    Ivy, Percy
    Karrison, Theodore G.
    Dekker, Allison
    Vokes, Everett E.
    Cohen, Ezra E. W.
    [J]. INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 677 - 683
  • [45] ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study
    Valerie Zielinski
    Markus Brunner
    Gregor Heiduschka
    Sven Schneider
    Rudolf Seemann
    Boban Erovic
    Dietmar Thurnher
    [J]. BMC Cancer, 12
  • [46] A phase II study of primary reirradiation in squamous cell carcinoma of head and neck
    Langendijk, Johannes A.
    Kasperts, Nicolien
    Leemans, Charles R.
    Doornaert, Patricia
    Slotman, Ben J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 78 (03) : 306 - 312
  • [47] A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck
    Huber, MH
    Lippman, SM
    Benner, SE
    Shirinian, M
    Dimery, IW
    Dunnington, JS
    Hong, WK
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (04): : 379 - 383
  • [48] The study on molecular targets of classification of head and neck squamous cell carcinoma.
    Chen, Wantao
    Cao, Wei
    Zhang, Ping
    Cui, Zhibin
    Xu, Qin
    Wang, Xu
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [49] ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study
    Zielinski, Valerie
    Brunner, Markus
    Heiduschka, Gregor
    Schneider, Sven
    Seemann, Rudolf
    Erovic, Boban
    Thurnher, Dietmar
    [J]. BMC CANCER, 2012, 12
  • [50] Phase II study of sunitinib malate in head and neck squamous cell carcinoma
    Nicholas W. Choong
    Mark Kozloff
    David Taber
    H. Shawn Hu
    James Wade
    Percy Ivy
    Theodore G. Karrison
    Allison Dekker
    Everett E. Vokes
    Ezra E. W. Cohen
    [J]. Investigational New Drugs, 2010, 28 : 677 - 683